ArticleJournal of veterinary internal medicine2018
Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.
Article in Journal of veterinary internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Mitotic activity: A systematic literature review of the assessment methodology and prognostic value in canine tumors.Veterinary pathology · 2024Pooled it
- Clinical Remission of an Unresectable Presumptive Haemangiosarcoma in a Dog Treated With Toceranib, Piroxicam, and Propranolol: A Case Report.Veterinary medicine and science · 2026Article
- Retrospective study of canine gastrointestinal tumors in Tokyo, Japan, 2012-2024.The Journal of veterinary medical science · 2026Article
- A CanineAnimals : an open access journal from MDPI · 2025Article
- Clinical Utility of Patient-Derived Cell-Based In Vitro Drug Sensitivity Testing for Optimizing Adjuvant Therapy in Dogs with Solid Tumors: A Retrospective Study (2019-2023).Animals : an open access journal from MDPI · 2025Article
- Safety and feasibility of lapatinib for the treatment of a EGFR1/HER-2-positive advanced gastrointestinal stromal tumor in a cat.Brazilian journal of veterinary medicine · 2025Article
- Retrospective Safety Evaluation of Combined Chlorambucil and Toceranib for the Treatment of Different Solid Tumours in Dogs.Animals : an open access journal from MDPI · 2024Article
- Successful post-incomplete resection management of gastrointestinal stromal tumor using imatinib based on adenosine triphosphate-based tumor sensitivity assay in a dog.The Canadian veterinary journal = La revue veterinaire canadienne · 2024Article
- Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future.Veterinary sciences · 2024Review
- Colonic gastrointestinal stromal tumor (GIST) presenting with colocolonic intussusception: A rare case report.The Canadian veterinary journal = La revue veterinaire canadienne · 2024Article
- Retrospective evaluation of toceranib phosphate (Palladia) use in the treatment of feline pancreatic carcinoma.The Canadian veterinary journal = La revue veterinaire canadienne · 2023Article
- Toceranib phosphate and firocoxib-mediated partial response in a dog with advanced intranasal sarcoma.The Journal of veterinary medical science · 2023Article
- Second era of molecular-targeted cancer therapies in dogs.The Journal of veterinary medical science · 2023Review
- Toceranib phosphate in the management of canine insulinoma: A retrospective multicentre study of 30 cases (2009-2019).Veterinary record open · 2022Article
- Gastrointestinal stromal tumor (GIST) presenting as a multilocular cystic intra-abdominal mass in a dog.BMC veterinary research · 2022Article
- Mutational Analysis ofVeterinary sciences · 2022Article
- VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications.Current oncology reports · 2022Review
- Characterization of receptor tyrosine kinase activation and biological activity of toceranib phosphate in canine urothelial carcinoma cell lines.BMC veterinary research · 2021Article
- Prognostic factors for dogs with surgically resected gastrointestinal stromal tumors.The Journal of veterinary medical science · 2021Article
- Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma.BMC veterinary research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundGastrointestinal stromal tumors (GISTs) are uncommon intestinal neoplasms in the dog. Literature regarding adjunctive therapy for GISTs in dogs is sparse. High-risk GISTs in humans respond to tyrosine kinase inhibition in the adjuvant setting.
objectivesTo review cases of toceranib phosphate use in dogs with GISTs and provide initial assessment of possible biological activity. A secondary aim was to evaluate patient and tumor characteristics for possible prognostic value. ANIMALS: Twenty-seven dogs with confirmed GISTs based on histopathology and immunohistochemistry treated with toceranib.
methodsRetrospective study in which cases of toceranib use in dogs with GIST were solicited using the American College of Veterinary Internal Medicine Oncology and Small Animal Internal Medicine listservs.
resultsFive of 7 dogs with gross disease experienced clinical benefit (71%; 3 complete responses, 1 partial response, 1 stable disease). These included 2 dogs with durable responses after toceranib discontinuation. Median progression-free interval (PFI) in dogs with gross disease was 110 weeks (range, 36-155 weeks). Median PFI in dogs with microscopic disease was 67 weeks (range, 9-257 weeks). Metastasis at diagnosis (P = 0.04) and high mitotic index (P < 0.001) were associated with shorter PFI in toceranib-treated dogs. CONCLUSIONS AND CLINICAL IMPORTANCE: Biological activity of toceranib is evident in dogs with gross disease. Metastasis of GIST at diagnosis, as well as high tumor mitotic index, was associated with shorter PFI in toceranib-treated dogs. Larger studies are needed to define postsurgical risk and refine the use of toceranib in dogs with gross and microscopic GIST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.